Trauma Adapted Yoga for Adolescents and Young Adults in Psychiatric Outpatient Treatment
NCT07934082, Not applicable, Recruiting, State University of New York - Upstate Medical University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Trauma Adapted Yoga for Adolescents and Young Adults in Psychiatric Outpatient Treatment | ClinicalTrials.gov |
| NCT number | NCT07934082 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 143 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | State University of New York - Upstate Medical University | ClinicalTrials.gov |
| Conditions | Psychiatric Disorders, Emotional Dysregulation | ClinicalTrials.gov |
| Interventions | Trauma Adapted Yoga, Physical Activity Control | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Positive Affect and Negative Affect-Extended. | Within 2 weeks before starting intervention and within 2 weeks post intervention | The Positive Affect and Negative Affect-Extended (PANAS-X) instrument consists of 30 items and captures the valence (positive and negative) and the arousal (activated or deactivated) of the mood descriptors (Watson \& Clark, 1994). As a result, PANAS-X30 makes it possible to measure positive (pleasant) and negative (unpleasant) and within both activated and deactivated affect states. This distinction is relevant in yoga studies, where effects are likely to be found in pleasant, deactivated emotions such as feeling calm, content, and relaxed. The following are examples for all four categories. Positive activated: active, enthusiastic, excited, inspired and, proud; Positive deactivated: at ease, serene, calm, relaxed, and content; Negative activated: afraid, scared, hostile, guilty, and ashamed; Negative deactivated: tired, sluggish, drowsy, dull, and bored (Watson \& Clark, 1994). | ClinicalTrials.gov |
| Primary | Multidimensional Assessment of Interoceptive Awareness (MAIA) | Within 2 weeks before starting intervention and within 2 weeks post intervention | The Multidimensional Assessment of Interoceptive Awareness (MAIA) is a 32-item self-report measure that assesses various dimensions of bodily awareness (Mehling, et. al., 2018). Respondents rate statements on a Likert scale, ranging from 0-1 (with 0 indicating "Never" and 5 indicating "Always"). Scores are totaled for each of 8 subscales that assess the respondents' tendency to notice, distract from, and worry about bodily sensations, maintain attention despite sensations, have awareness of connection between body and emotion, self-regulate, listen to the body for insight, and to trust ones' own body. Higher scores indicate more interoceptive awareness (Mehling, et. al., 2018). | ClinicalTrials.gov |
| Primary | Difficulties in Emotion Regulation Scale (DERS) | Within 2 weeks before starting intervention and within 2 weeks post intervention | The Difficulties in Emotion Regulation Scale (DERS) is a self-report measure that is well validated and frequently utilized for assessing emotion regulation deficits. This measure has good reliability and validity with adolescents and adults of all ages and has been validated internationally. This scale consists of six subscales, ranging from five to eight items each, with a total of 36 total items. Many of the items for the scales begin with "When I'm upset", and respondents are asked to respond with how often the items are applicable to themselves. Responses range from 1 to 5, where 1 = almost never, 2 = sometimes, 3 = about half the time, 4 = most of the time, and 5 = almost always (Kaufman et al., 2016). | ClinicalTrials.gov |
| Secondary | The PTSD Checklist for DSM-5 (PCL-5) for young adults | Within 2 weeks before starting intervention and within 2 weeks post intervention | The PTSD Checklist for DSM-5 (PCL-5) is a commonly used self-rated measure utilized to measure DSM-5 PTSD symptoms. This scale assesses symptoms across the four DSM-5 clusters: intrusions (Criterion B), avoidance of trauma reminders (Criterion C), negative alterations in cognitions and mood (Criterion D), and alterations in arousal and reactivity (Criterion E). This measure consists of 20 items with responses ranging from 0 to 4 with 0 = "not at all", 1 = "a little bit", 2 = "moderately", 3 = "quite a bit", to 4 = "extremely". The PCL-5 has been examined across several different languages and settings. | ClinicalTrials.gov |
| Secondary | Heart Rate Variability | To be measured in 2 weeks leading up to and during the intervention | Heart rate variability (HRV), or the beat-to-beat alteration in heart rate, offers a noninvasive indicator of the autonomic nervous system's activity. HRV has been used as a proxy for health and fitness and as an indicator of autonomic regulation. Low HRV-indicating reduced parasympathetic cardiac control-was associated with sleep problems and difficulty regulating emotions, while yoga practice was associated with increased HRV. HRV can be measured with a good quality activity bracelet and an App belonging to that. HRV data for the comparison group will be recorded with an identical time interval, during leisure time physical activity. This will be recorded once pre intervention and once post intervention. | ClinicalTrials.gov |
| Secondary | DNAm | To be measured in 2 weeks leading up to and during the intervention | DNAm is a well-known form of an epigenetic process characterized by adding/removing methyl groups to cytosine-phosphate-guanine (CpG) sites, leading to changes in transcriptional ability without changes in the genetic code. Because it responds to environment yet is stable enough to capture biologically significant adaptation, DNAm represents a mechanism through which experiences can leave biological imprints via epigenetics. Epigenetics has been extensively studied in relation to stress-responsive neuroendocrine signaling, neuroplasticity, inflammation, and behavioral health outcomes, making it highly relevant to interventions targeting improvement in body regulation and emotional processing (Bagot et al., 2014; Cecil et al., 2020; Murgatroyd et al., 2009). Previous studies have consistently found methylation differences related to psychological stress in individuals with PTSD in HPA-regulating genes (such as NR3C1, FKBP5); additionally, DNAm changes in response to psychotherapy and m | ClinicalTrials.gov |
| Secondary | Brief Symptom Inventory (BSI) | To be measured in 2 weeks leading up to and during the intervention | The Brief Symptom Inventory (BSI) is a self-rated measure of general psychopathology and psychological distress. The BSI contains 53 items reflecting psychological symptom patterns of psychiatric patients and non-patients. It comprises nine primary symptoms' scales and the global severity index (GSI). The primary symptom scales are: Anxiety, Depression, Interpersonal Sensitivity, Hostility, Obsessive Compulsiveness, Psychoticism, Paranoid Ideations, Phobic Anxiety, and Somatization. The answers are given on a five-point scale, from 0 = "not at all" to 4 = "extremely." | ClinicalTrials.gov |
| Secondary | Child and Youth Resilience Measure- Revised (CYRM-R) | To be measured in 2 weeks leading up to and during the intervention | The Child and Youth Resilience Measure- Revised (CYRM-R) is a self-report measures of social ecological resilience (Resilience Research Centre, 2018). The CYRM-R is suitable for youth aged 10-23. It consists of 17-items and can be scored on 3- or 5-point Likert scales. The items in the measure are all positively worded and therefore scoring involves simple summing of responses. It can be used to evaluate the efficacy of interventions to build and maintain resilience. The measure has been translated into more than 20 languages and used in more than 150 research studies (Resilience Research Centre, 2018). | ClinicalTrials.gov |
| Secondary | Child PTSD Symptom Scale for DSM-5 (CPSS-5) for 12-18 | To be measured in 2 weeks leading up to and during the intervention | The Child PTSD Symptom Scale for DSM-5 (CPSS-5) is a 24-item self-report measure utilized to measure posttraumatic stress disorder symptoms and severity, and to assist in diagnosis for children and adolescents ages 8-18 (Fao et. Al., 2018). Items 1-20 assess for the presence of various PTSD symptoms and yield an overall symptom severity score. Items 1-24 measure the functional impairment of endorsed symptoms (Fao et. Al., 2018). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 12
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)